Inactive Instrument

CS MEDICA A/S

Equities

CSMED

DK0061668225

CS Medica has signed white label partnership for launch in Italy

Published on 01/07/2025 at 02:17 am EST - Modified on 01/07/2025 at 02:18 am EST

Finwire - Translated by Marketscreener - See original

CS MEDICA A/S

-6.15%

Medical cannabis company CS Medica, through its subsidiary Cannordic, has signed a white label partnership for launch in Italy.

The first order, worth DKK 1,1 million, includes Pain & Arthritis Gel and Wound Gel with launch planned for the second quarter of 2025.

The company is in discussions to expand the range and global distribution to over 50 countries in the future.

Latest news about CS MEDICA A/S

Apr. 01	CS Medica A/S Elects Jens Hagelskjær as Board Director	CI
Jan. 21	CS Medica A/S Reports Earnings Results for the First Quarter Ended December 31, 2025	CI
Nov. 30	CS Medica A/S Reports Earnings Results for the Full Year Ended September 30, 2025	CI
Nov. 30	CS Medica A/S Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2025	CI
Nov. 30	CS Medica A/S Provides Revenue Guidance for the Fourth Quarter of 2025	CI
25-05-17	CS Medica A/S Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2025	CI
25-04-16	CS Medica A/S Approves Board Changes	CI
25-03-31	CS Medica A/S Announces Co-CEO Changes	CI
25-03-31	CS Medica A/S Reports Earnings Results for the First Quarter Ended December 31, 2024	CI
25-02-17	CS Medica A/S Announces Board Changes	CI
25-02-17	CS Medica A/S Announces CEO Changes	CI
25-01-09	Ahead of delisting: CS Medica temporarily suspends all non-revenue generating activities	FW
25-01-09	CS Medica has today the last trading day on Spotlight before delisting	FW
25-01-07	CS Medica has signed white label partnership for launch in Italy	FW
25-01-06	CS Medica Unit Secures Partnership Deal in Italy	MT

Chart CS MEDICA A/S

Duration

Period

CSMED: Dynamic Chart

Company Profile

Employees

Sector

Calendar

May. 17 - Earnings release - Q2 2026

More about the company